Weight-loss drugmaker Eli Lilly delivered lower sales and earnings per share than expected in the third quarter, blaming high ...

Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to turn the company into the world’s first $1tn drugmaker by market value. But war stories about ...

Eli Lilly’s chunky valuation means it has little room for error. The shares have more than tripled since the start of 2022 to ...

However, according to the FT, Lilly has not proven the drug’s possibilities ... Leqembi (lecanemab). More on Eli Lilly ...